WHO Technical Report Series

1033

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-fifth report

World Health Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing diseases prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaption. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. To purchase WHO publications, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; http://www.who.int/bookorders).

WHO Technical Report Series
1033

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-fifth report

This report contains the views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

World Health Organization

WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-fifth report

(WHO Technical Report Series, No. 1033)

ISBN 978-92-4-002090-0 (electronic version)
ISBN 978-92-4-002091-7 (print version)

ISSN 0512-3054

Suggested citation. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-fifth report. Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1033). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Contents

Abbreviations vi

WHO Expert Committee on Specifications for Pharmaceutical Preparations x

Declarations of interest xvi

OPEN SESSION 1

Introduction and welcome 1

I. Expert Committee on Specifications for Pharmaceutical Preparations processes and procedures 1

II. Update on new guidelines, norms and standards 2

III. Technical agenda topics of the Fifty-fifth Expert Committee on Specifications for Pharmaceutical Preparations 2

IV. Points of discussion 3

PRIVATE AND CLOSED SESSIONS 5

Opening 5

1. General policy 7

1.1 Process for development of WHO norms and standards 7

2. Quality assurance: collaboration initiatives 8

2.1 International Meeting of World Pharmacopoeias 8

3. Nomenclature, terminology and databases 9

3.1 International nonproprietary names for pharmaceutical substances 9

3.2 Quality assurance terminology 10

3.3 Guidelines and guidance texts adopted by the Expert Committee on Specifications for Pharmaceutical Preparations 10

4. Quality control – national laboratories 11

4.1 External Quality Assurance Assessment Scheme 11

4.1.1 Final report on phase 9 11

4.1.2 Update on phase 10 12

5. Quality control – specifications and tests 13

5.1 *The International Pharmacopoeia* 13

5.2 General chapters 13

5.2.1 Dissolution test for oral dosage forms 13

5.2.2 General identification tests 14

5.2.3 Test for histamine-like substances 14

5.3 General monographs for dosage forms 15

5.3.1 Powders for inhalation 15

5.3.2 Liquid preparations for oral use 15

5.4 Specifications and draft monographs for medicines, including paediatric medicines, and candidate medicines for COVID-19 16

5.4.1 COVID-19 therapeutics 16

5.4.2 Antiviral medicines, including antiretrovirals 17
5.4.3 Medicines for tropical diseases 18
5.4.4 Medicines for maternal, newborn, child and adolescent health 19
5.4.5 Excipients 20
5.5 Update on the virtual informal consultation on Screening Technologies, Laboratory Tools and Pharmacopoeial Specifications for Medicines 20

6. Quality control: international reference materials 22
6.1 Update on International Chemical Reference Substances 22

7. Quality assurance: good manufacturing practice and inspection 23
7.1 Inspection guidelines and good practices with partner organizations 23
7.1.1 Revision of good manufacturing practices for sterile products 23
7.1.2 Good manufacturing practices for radiopharmaceuticals for investigational use 23
7.2 Approaches to carryover limits in cleaning validation 24
7.3 Water for pharmaceutical use 25
7.4 Guideline on data integrity 26
7.5 Points to consider for manufacturers and inspectors: environmental aspects of manufacturing for the prevention of antimicrobial resistance 27
7.6 Recommendations from the virtual consultation on good practices for health products and inspection 29

8. Quality assurance: distribution and supply chain 30
8.1 Shelf life for supply and procurement of medical products 30
8.1.1 Revision to the guideline on remaining shelf life 30
8.2 Updated and new WHO guidance, procedures and operational documents for pharmaceutical procurement 31
8.2.1 World Health Organization/United Nations Population Fund prequalification guidance on condoms 31

9. Regulatory guidance and model schemes 33
9.1 Proposal to waive in vivo bioequivalence requirements for medicines on the *WHO Model List of Essential Medicines* 33
9.2 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce 36
9.3 Good practices in regulatory decision-making 38
9.3.1 Good reliance practices in the regulation of medical products 38
9.3.2 Good regulatory practices in the regulation of medical products 39
9.4 Update on WHO-listed authorities 40
9.5 Recommendations from the virtual consultation on Regulatory Guidance for Multisource Products 41

10. Miscellaneous: update on activities related to COVID-19 43
10.1 Oxygen specifications 43
10.2 Therapeutic specifications 43
10.3 Existing guidance 44
10.4 New activities 44

11. Closing remarks 45

12. Summary and recommendations 46

12.1 Guidelines and decisions adopted and recommended for use 47
12.2 Texts adopted for inclusion in *The International Pharmacopoeia* 47
12.3 Recommendations 49

Acknowledgements 52

References 71

Annex 1

Guidelines and guidance texts adopted by the Expert Committee on Specifications for Pharmaceutical Preparations 75

Annex 2

Points to consider when including Health-Based Exposure Limits (HBELs) in cleaning validation 93

Annex 3

Good manufacturing practices: water for pharmaceutical use 111

Annex 4

Guideline on data integrity 135

Annex 5

World Health Organization/United Nations Population Fund Recommendations for condom storage and shipping temperatures 161

Annex 6

World Health Organization/United Nations Population Fund Guidance on testing of male latex condoms 167

Annex 7

World Health Organization/United Nations Population Fund guidance on conducting post-market surveillance of condoms 189

Annex 8

WHO "Biowaiver List": proposal to waive in vivo bioequivalence requirements for *WHO Model List of Essential Medicines* immediate-release, solid oral dosage forms 197

Annex 9

Guidelines on the implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce 205

Annex 10

Good reliance practices in the regulation of medical products: high level principles and considerations 237

Annex 11

Good regulatory practices in the regulation of medical products 269

Abbreviations

ACT	Access to COVID-19 Tools
ALCOA	attributable, legible, contemporaneous, original and accurate
AMR	antimicrobial resistance
API	active pharmaceutical ingredient
AQL	acceptance quality level
AUC	area under the curve
BCS	Biopharmaceutics Classification System
BE	bioequivalence
BMDL	benchmark dose level
BPW	bulk purified water
BWFI	bulk water for injection
CAPA	corrective and preventive action
CpK	process capability (*also saved under P*)
CPP	certificate of a pharmaceutical product
DABT	Diplomate of the American Board of Toxicology
DIRA	data integrity risk assessment
EAP	WHO Expert Advisory Panel on *The International Pharmacopoeia* and Pharmaceutical Preparations
ECSPP	Expert Committee on Specifications for Pharmaceutical Preparations
EDI	[illegible]